Correction to: Decitabine/Cedazuridine: First Approval
نویسندگان
چکیده
منابع مشابه
Durvalumab: First Global Approval
Intravenous durvalumab (Imfinzi™; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80), resulting in enhanced T-cell responses against cancer cells. The US FDA has granted durvalumab accelerated approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progress...
متن کاملApproval of the first biosimilar antibodies in Europe
In a defining moment for the European Medicines Agency (EMA) and the biopharmaceutical industry, on June 27, 2013 EMA's Committee for Medicinal Products for Human Use adopted a positive opinion for two biosimilar infliximab products (Celltrion's Remsima® and Hospira's Inflectra®), and recommended that they be approved for marketing in the European Union (EU). The European Commission's decision ...
متن کاملDaptomycin: a review 4 years after first approval.
Daptomycin is the first approved member of a new class of antibiotics, namely the cyclic lipopeptides. Daptomycin has rapid bactericidal activity against Gram-positive pathogens. It acts by penetrating into the bacterial cell wall with consecutive formation of pores, loss of electrical membrane potential and inhibition of peptidoglycan synthesis. As the mode of action of daptomycin is 'concentr...
متن کاملIs Approval Voting Optimal Given Approval Votes?
Some crowdsourcing platforms ask workers to express their opinions by approving a set of k good alternatives. It seems that the only reasonable way to aggregate these k-approval votes is the approval voting rule, which simply counts the number of times each alternative was approved. We challenge this assertion by proposing a probabilistic framework of noisy voting, and asking whether approval v...
متن کاملTwo Longer Corrections to Elliptic Curves from Langlands First Correction
Difficulty. The use of Proposition 5.5 to obtain Proposition 5.6 is inadequate if the reduction map rp on the set of distinct points among {P,Q,PQ} is not oneone. For example, if P , Q, and PQ are distinct and rp(P ) = rp(Q) = rp(PQ), then Proposition 5.5 shows that the intersection multiplicity for rp(P ) is ≥ 1, but it does not produce either a second or a third point on rp of the line. Thus ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drugs
سال: 2020
ISSN: 0012-6667,1179-1950
DOI: 10.1007/s40265-020-01453-2